FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2786125814> ?p ?o ?g. }

• W2786125814 endingPage "1635" @default.
• W2786125814 startingPage "1622" @default.
• W2786125814 abstract "A noninvasive topical ocular therapy for the treatment of neovascular or “wet” age-related macular degeneration would provide a patient administered alternative to the current standard of care, which requires physician administered intravitreal injections. This manuscript describes a novel strategy for the use of in vivo models of choroidal neovascularization (CNV) as the primary means of developing SAR related to efficacy from topical administration. Ultimately, this effort led to the discovery of acrizanib (LHA510), a small-molecule VEGFR-2 inhibitor with potency and efficacy in rodent CNV models, limited systemic exposure after topical ocular administration, multiple formulation options, and an acceptable rabbit ocular PK profile." @default.
• W2786125814 created "2018-02-23" @default.
• W2786125814 creator A5000292844 @default.
• W2786125814 creator A5000841905 @default.
• W2786125814 creator A5001803152 @default.
• W2786125814 creator A5001942826 @default.
• W2786125814 creator A5005667052 @default.
• W2786125814 creator A5011169885 @default.
• W2786125814 creator A5014013076 @default.
• W2786125814 creator A5017419212 @default.
• W2786125814 creator A5020478581 @default.
• W2786125814 creator A5020752011 @default.
• W2786125814 creator A5023642643 @default.
• W2786125814 creator A5028807874 @default.
• W2786125814 creator A5029492553 @default.
• W2786125814 creator A5031339860 @default.
• W2786125814 creator A5035149494 @default.
• W2786125814 creator A5039608468 @default.
• W2786125814 creator A5047432897 @default.
• W2786125814 creator A5052348924 @default.
• W2786125814 creator A5053427641 @default.
• W2786125814 creator A5062737096 @default.
• W2786125814 creator A5064611440 @default.
• W2786125814 creator A5069262561 @default.
• W2786125814 creator A5070284691 @default.
• W2786125814 creator A5072728763 @default.
• W2786125814 creator A5073044147 @default.
• W2786125814 creator A5075226733 @default.
• W2786125814 creator A5077115392 @default.
• W2786125814 creator A5080424082 @default.
• W2786125814 creator A5082885356 @default.
• W2786125814 creator A5082982631 @default.
• W2786125814 creator A5083005501 @default.
• W2786125814 creator A5083352578 @default.
• W2786125814 creator A5085025467 @default.
• W2786125814 creator A5085060131 @default.
• W2786125814 creator A5086038672 @default.
• W2786125814 date "2018-02-05" @default.
• W2786125814 modified "2023-10-10" @default.
• W2786125814 title "The Discovery of <i>N</i>-(1-Methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1<i>H</i>-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration" @default.
• W2786125814 cites W148577536 @default.
• W2786125814 cites W1802218256 @default.
• W2786125814 cites W181373276 @default.
• W2786125814 cites W1971080722 @default.
• W2786125814 cites W1982294397 @default.
• W2786125814 cites W1985359220 @default.
• W2786125814 cites W1985712533 @default.
• W2786125814 cites W1992955876 @default.
• W2786125814 cites W1993399691 @default.
• W2786125814 cites W2004117352 @default.
• W2786125814 cites W2008901562 @default.
• W2786125814 cites W2010804179 @default.
• W2786125814 cites W2011095792 @default.
• W2786125814 cites W2018516156 @default.
• W2786125814 cites W2019875709 @default.
• W2786125814 cites W2024460795 @default.
• W2786125814 cites W2039627373 @default.
• W2786125814 cites W2047399850 @default.
• W2786125814 cites W2078916806 @default.
• W2786125814 cites W2085712747 @default.
• W2786125814 cites W2086475585 @default.
• W2786125814 cites W2124415048 @default.
• W2786125814 cites W2126522226 @default.
• W2786125814 cites W2134161293 @default.
• W2786125814 cites W2158933399 @default.
• W2786125814 cites W2184100967 @default.
• W2786125814 cites W2230606183 @default.
• W2786125814 cites W2270373393 @default.
• W2786125814 cites W2346199162 @default.
• W2786125814 cites W2567416294 @default.
• W2786125814 cites W2619267093 @default.
• W2786125814 cites W2952830279 @default.
• W2786125814 cites W3141534998 @default.
• W2786125814 doi "https://doi.org/10.1021/acs.jmedchem.7b01731" @default.
• W2786125814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29400470" @default.
• W2786125814 hasPublicationYear "2018" @default.
• W2786125814 type Work @default.
• W2786125814 sameAs 2786125814 @default.
• W2786125814 citedByCount "21" @default.
• W2786125814 countsByYear W27861258142018 @default.
• W2786125814 countsByYear W27861258142019 @default.
• W2786125814 countsByYear W27861258142020 @default.
• W2786125814 countsByYear W27861258142021 @default.
• W2786125814 countsByYear W27861258142022 @default.
• W2786125814 countsByYear W27861258142023 @default.
• W2786125814 crossrefType "journal-article" @default.
• W2786125814 hasAuthorship W2786125814A5000292844 @default.
• W2786125814 hasAuthorship W2786125814A5000841905 @default.
• W2786125814 hasAuthorship W2786125814A5001803152 @default.
• W2786125814 hasAuthorship W2786125814A5001942826 @default.
• W2786125814 hasAuthorship W2786125814A5005667052 @default.
• W2786125814 hasAuthorship W2786125814A5011169885 @default.
• W2786125814 hasAuthorship W2786125814A5014013076 @default.
• W2786125814 hasAuthorship W2786125814A5017419212 @default.
• W2786125814 hasAuthorship W2786125814A5020478581 @default.
• W2786125814 hasAuthorship W2786125814A5020752011 @default.
• W2786125814 hasAuthorship W2786125814A5023642643 @default.
• W2786125814 hasAuthorship W2786125814A5028807874 @default.

• next